Lifesci Capital Has Negative Estimate for Oculis Q1 Earnings

Oculis Holding AG (NASDAQ:OCS) – Stock analysts at Lifesci Capital reduced their Q1 2026 earnings per share estimates for shares of Oculis in a research report issued on Wednesday, March 4th. Lifesci Capital analyst P. Dolezal now forecasts that the company will earn ($0.46) per share for the quarter, down from their prior estimate of ($0.40). Lifesci Capital currently has a “Outperform” rating and a $55.00 target price on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. Lifesci Capital also issued estimates for Oculis’ Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.49) EPS and FY2026 earnings at ($1.89) EPS.

Oculis (NASDAQ:OCS) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). Oculis had a negative return on equity of 62.12% and a negative net margin of 8,173.41%.The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.14 million.

Several other research analysts also recently weighed in on OCS. Wall Street Zen raised shares of Oculis from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Thursday, January 22nd. Chardan Capital reissued a “buy” rating and set a $51.00 target price on shares of Oculis in a research note on Tuesday, November 11th. Needham & Company LLC raised their target price on Oculis from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. began coverage on Oculis in a report on Friday, December 19th. They set an “overweight” rating and a $38.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.50.

Oculis Price Performance

NASDAQ OCS opened at $26.96 on Friday. The company has a current ratio of 5.96, a quick ratio of 4.47 and a debt-to-equity ratio of 0.01. Oculis has a 1 year low of $14.00 and a 1 year high of $30.68. The company has a market cap of $1.56 billion, a PE ratio of -11.88 and a beta of 0.29. The stock’s 50-day moving average price is $26.16 and its two-hundred day moving average price is $21.55.

Institutional Investors Weigh In On Oculis

Several large investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its position in Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after acquiring an additional 1,000 shares in the last quarter. Aventura Private Wealth LLC acquired a new position in shares of Oculis during the 4th quarter worth $80,000. Millennium Management LLC acquired a new stake in shares of Oculis in the 4th quarter valued at $312,000. Bosun Asset Management LLC bought a new stake in Oculis in the second quarter worth $378,000. Finally, Marshall Wace LLP acquired a new position in Oculis during the second quarter worth $393,000. Institutional investors own 22.30% of the company’s stock.

Oculis News Roundup

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Company is actively presenting at multiple investor conferences in March and reiterated late‑stage pipeline milestones — Privosegtor received breakthrough therapy designation (optic neuritis), OCS‑01 topline readout expected in Q2 2026, and Licaminlimab advancing as a genotype‑driven program — supporting longer‑term upside for the stock. Oculis to Participate in Upcoming Investor Conferences
• Positive Sentiment: HC Wainwright raised a price target to $44 (published by AmericanBankingNews), which can provide technical/psychological support despite other model reductions. HC Wainwright Boosts Oculis Price Target
• Neutral Sentiment: Oculis filed its audited 2025 consolidated financial statements and MD&A on Form 20‑F — useful for diligence but largely informational unless the filings reveal unexpected surprises. Oculis Publishes 2025 Consolidated Financial Statements
• Neutral Sentiment: Company published notifications that RSUs granted to directors have vested and been settled — standard disclosure; could be neutral if shares are retained, or slightly negative if it leads to insider selling. Oculis Publishes Notifications of Transactions
• Negative Sentiment: Multiple analyst teams (LifeSci Capital and HC Wainwright) cut near‑term quarterly and FY2026 EPS forecasts, trimming expectations for Q1–Q4 and lowering FY numbers — these downward revisions increase near‑term earnings uncertainty and likely triggered selling pressure. (Analyst notes summarized on MarketBeat.) Analyst Estimate Reductions

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.